Navigation Links
Helix BioPharma announces $16.9 million private placement of common shares
Date:12/17/2007

AURORA, Ontario, Dec. 17 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that it has received subscriptions for the purchase, by way of private placement, of a total of 10,040,000 common shares at $1.68 per share, for gross proceeds totaling CDN$16,867,200. Proceeds from the placement will be used for working capital, primarily to fund the Company's research and development initiatives.

The Company expects to close the private placement within the next ten days.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains forward-looking statements regarding a proposed private placement and the Company's activities, which statements can be identified by the words "will", "anticipates", and "developing". Actual results or events could differ materially from these forward-looking statements due to numerous factors, including without limitation, the risk that the proposed placement may not close as anticipated or at all, research & development risks, Helix's need for additional future capital, the risk of unanticipated expenses, and possible changes in business strategy or plans. These and other risks and uncertainties are contained in Helix's latest Annual Information Form at http://www.sedar.com. Forward-looking statements and information are based on the assumptions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement or information should those assumptions or expectations, or other circumstances change.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., ... today that it is launching two new additions of its award-winning cloud-based platform ... capabilities at the DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. ...
(Date:6/16/2017)... Massachusetts (PRWEB) , ... June 16, 2017 , ... ... medical device compliance and commercialization, has just announced two more sessions of its ... the series will focus on the world of online templates for design control ...
(Date:6/15/2017)... Colorado (PRWEB) , ... June 15, 2017 , ... ... the synthetic auxin herbicides give farmers new options for managing Palmer amaranth and ... of America (WSSA) say special precautions are necessary. Auxin herbicides are known to ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
Breaking Biology News(10 mins):